Jefferies Group LLC reaffirmed their buy rating on shares of FibroGen, Inc (NASDAQ:FGEN) in a research note issued to investors on Tuesday. The firm currently has a $75.00 target price on the biopharmaceutical company’s stock.

FGEN has been the topic of a number of other research reports. Goldman Sachs Group, Inc. (The) downgraded FibroGen from a buy rating to a neutral rating and set a $31.00 price target on the stock. in a report on Friday, July 21st. BidaskClub downgraded FibroGen from a strong-buy rating to a buy rating in a report on Monday, July 31st. Zacks Investment Research downgraded FibroGen from a hold rating to a sell rating in a report on Monday, May 8th. Citigroup Inc. reiterated a buy rating and set a $48.00 price target on shares of FibroGen in a report on Monday, June 26th. Finally, William Blair reiterated an outperform rating on shares of FibroGen in a report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. FibroGen currently has a consensus rating of Buy and an average target price of $56.86.

FibroGen (NASDAQ:FGEN) traded down 9.80% during trading on Tuesday, reaching $44.65. The company had a trading volume of 1,493,204 shares. The stock has a 50 day moving average price of $33.32 and a 200 day moving average price of $27.67. FibroGen has a 12 month low of $15.60 and a 12 month high of $49.50. The firm’s market capitalization is $3.12 billion.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The company had revenue of $29 million during the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative return on equity of 71.32% and a negative net margin of 105.59%. On average, equities research analysts predict that FibroGen will post ($1.86) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group LLC Reiterates “Buy” Rating for FibroGen, Inc (NASDAQ:FGEN)” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/09/jefferies-group-llc-reiterates-buy-rating-for-fibrogen-inc-nasdaqfgen.html.

In related news, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $27.70, for a total transaction of $1,070,217.20. Following the completion of the sale, the chief executive officer now owns 3,345,941 shares of the company’s stock, valued at $92,682,565.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction on Monday, May 15th. The shares were sold at an average price of $27.75, for a total value of $524,475.00. Following the sale, the chief executive officer now directly owns 3,345,941 shares of the company’s stock, valued at approximately $92,849,862.75. The disclosure for this sale can be found here. Insiders have sold 404,974 shares of company stock worth $12,515,438 in the last quarter. 14.90% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in FGEN. Swiss National Bank boosted its stake in FibroGen by 20.0% in the second quarter. Swiss National Bank now owns 99,100 shares of the biopharmaceutical company’s stock worth $3,201,000 after buying an additional 16,500 shares during the last quarter. Principal Financial Group Inc. boosted its stake in FibroGen by 2.5% in the second quarter. Principal Financial Group Inc. now owns 139,465 shares of the biopharmaceutical company’s stock worth $4,504,000 after buying an additional 3,420 shares during the last quarter. Airain ltd boosted its stake in FibroGen by 56.6% in the second quarter. Airain ltd now owns 14,971 shares of the biopharmaceutical company’s stock worth $484,000 after buying an additional 5,409 shares during the last quarter. Prudential Financial Inc. boosted its stake in FibroGen by 9.6% in the second quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock worth $14,496,000 after buying an additional 39,430 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in FibroGen by 589.1% in the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 6,327 shares during the last quarter. 43.45% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.